Endocrinology, Diabetes and Metabolism最新文献

{"title":"Shortened Relative Leukocyte Telomere Length Is Associated With Polycystic Ovary Syndrome and Metabolic Traits","authors":"Raymond N.C. Chan,&nbsp;Chuiguo Huang,&nbsp;Noel Y. H. Ng,&nbsp;Henry C. H. Tam,&nbsp;Claudia H. T. Tam,&nbsp;Feifei Cheng,&nbsp;Kwun Kiu Wong,&nbsp;Mai Shi,&nbsp;Alex C. W. Ng,&nbsp;Atta Y. T. Tsang,&nbsp;Chi Chiu Wang,&nbsp;Lai Ping Cheung,&nbsp;Wing Hung Tam,&nbsp;Mugdha V. Joglekar,&nbsp;Anandwardhan A. Hardikar,&nbsp;Alicia J. Jenkins,&nbsp;Juliana C. N. Chan,&nbsp;Cadmon K. P. Lim,&nbsp;Ronald C. W. Ma","doi":"10.1002/edm2.70030","DOIUrl":"https://doi.org/10.1002/edm2.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Polycystic ovary syndrome (PCOS) is one of the commonest gyneco-endocrine disorders amongst women of reproductive age. Whether PCOS and cardiometabolic traits in PCOS patients are associated with shortened telomere length (TL) or relative leukocyte telomere length (rLTL) remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>214 women with PCOS and 214 age-matched women were recruited. rLTL was measured with an updated quantitative real-time PCR protocol and reported as ΔΔCt between telomere and a single-copy gene encoding β-globin relative to a normalisation control. A two-way Mendelian randomization analysis using the UK Biobank Resource was performed to assess the causal relationship between rLTL and PCOS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Women with PCOS had significantly shortened rLTL (PCOS: 0.5 ± 0.7; control: 0.8 ± 0.6; <i>p</i> &lt; 0.001). Longer rLTL was associated with a lower risk of PCOS after adjusting for age, history of smoking and other cardiometabolic traits (OR: 0.503; 95% CI: 0.342–0.730; <i>p</i> &lt; 0.001). Longer rLTL was associated with reduced risk of dyslidpidemia (OR: 0.563; 95% CI: 0.450–0.968; <i>p</i> = 0.042) in PCOS patients. PCOS subjects with rLTL shorter than mean of the rLTL of control subjects had an elevated risk of dysglycemia (OR: 2.09; 95% CI: 1.04–4.29; <i>p</i> = 0.040). No causal relationships were found between rLTL and PCOS in the Mendelian randomization study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Women with PCOS have significantly reduced rLTL and shorter LTL may be associated with cardiometabolic risk factors in PCOS subjects. There are no causal relationship between genetically determined PCOS and TL or vice versa.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Serum IL-17A, Renal Function and Diabetic Retinopathy in Type 2 Diabetes Mellitus: Evidence From a Chinese Han Population","authors":"Wensu Wang,&nbsp;Yan Huang,&nbsp;Jianguo Shen,&nbsp;Li Jin,&nbsp;Zhuo Chen","doi":"10.1002/edm2.70033","DOIUrl":"https://doi.org/10.1002/edm2.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Evidence suggested that IL-17A was associated with renal function in type 2 diabetes. We used ultra-sensitive measurement to detect the concentration of IL-17A in human peripheral blood and explored the association of IL-17A with diabetic kidney disease (DKD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We recruited 138 participants from the Shanghai Diabetes Institute Inpatient Database of Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Eighty-four individuals diagnosed as DKD were cases, and 54 type 2 diabetes individuals without DKD or diabetic retinopathy (DR) were controls. The concentration of serum IL-17A was detected by the High Sensitivity Immunoassay Quantitative Kit. Data was analysed by SAS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The concentration of serum IL-17A in our population ranged from 0.07 pg/mL to 2.96 pg/mL with the median of 0.502 pg/mL. Our results suggested that the level of serum IL-17A in DKD case group was higher than in the control (<i>P</i> _{<i>unadjusted</i>} = 0.0496, <i>P</i> _{<i>adjusted</i>} = 0.0298). And serum creatinine, eGFR, ACR were used as indicators of renal function. Serum creatinine and ACR were positive correlated with the level of serum IL-17A (<i>P</i> _{<i>adjusted</i>} = 0.0148; <i>P</i> _{<i>adjusted</i>} = 0.0369), while eGFR showed a negative correlation (<i>P</i> _{<i>adjusted</i>} = 0.0167). Additionally, the level of serum IL-17A was also significantly higher in DR case group compared with the control group (<i>p</i> = 0.0224).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Serum IL-17A level is associated with renal function decline and diabetic retinopathy in patients with type 2 diabetes in a Chinese Han population. Our results suggested that IL-17A may be a potential biomarker of DKD and DR.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Triglyceride-Glucose Index and Microvascular Complications in Patients With Early- Onset of Type 2 Diabetes Mellitus","authors":"Liu Ran,&nbsp;Yang Han,&nbsp;Hao Zhaohu,&nbsp;Shao Hailin","doi":"10.1002/edm2.70027","DOIUrl":"https://doi.org/10.1002/edm2.70027","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to explore the potential correlation between the triglyceride-glucose (TyG) index and diabetic nephropathy (DN) and diabetic retinopathy (DR) in patients with early-onset type 2 diabetes mellitus (T2DM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>This cross-sectional study statistically analysed TyG index levels across DN and DR stages in patients with early-onset and non-early-onset T2DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients</h3>\u0000 \u0000 <p>A total of 1530 T2DM patients were enrolled between January 2017 and August 2023 at Tianjin Fourth Central Hospital in Tianjin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Measurements</h3>\u0000 \u0000 <p>Correlation analysis and logistic regression were used to examine the association between the TyG index and microvascular complications. Kaplan–Meier plots and Cox regression analyses were employed to evaluate the effects of the TyG index on DN incidence. TyG index's diagnostic ability for DN was explored using the area under the receiver operating characteristic curve.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In patients with early-onset T2DM, the TyG index gradually decreased with DR aggravation and gradually increased with DN aggravation, showing a negative correlation with DR and a positive correlation with DN in patients with early-onset T2DM; logistic regression analysis suggested that the TyG index was an independent risk factor for DN (OR = 1.623, 95% CI = 1.175–2.242). The Cox regression analysis and Kaplan–Meier plots suggested that higher TyG was associated with an earlier incidence of DN in patients with early-onset T2DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In patients with early-onset T2DM, the TyG index could be used to evaluate the risk of microvascular complications, with elevated TyG levels potentially indicating high risk of insulin– resistance related renal injury.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study","authors":"Ahmed Y. Azzam,&nbsp;Muhammed Amir Essibayi,&nbsp;Nathan Farkas,&nbsp;Mohammed A. Azab,&nbsp;Mahmoud M. Morsy,&nbsp;Osman Elamin,&nbsp;Adam Elswedy,&nbsp;Ahmed Saad Al Zomia,&nbsp;Hammam A. Alotaibi,&nbsp;Ahmed Alamoud,&nbsp;Oday Atallah,&nbsp;Hana J. Abukhadijah,&nbsp;Adam A. Dmytriw,&nbsp;Amanda Baker,&nbsp;Deepak Khatri,&nbsp;Neil Haranhalli,&nbsp;David J. Altschul","doi":"10.1002/edm2.70019","DOIUrl":"https://doi.org/10.1002/edm2.70019","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Idiopathic intracranial hypertension (IIH) is a neurological disorder characterised by elevated intracranial pressure (ICP), predominantly affecting obese women of reproductive age. While GLP-1 receptor agonists have shown promise in IIH management, the potential of dual GIP/GLP-1 receptor activation through tirzepatide remains unexplored. This study aimed to evaluate tirzepatide's efficacy as an adjunctive therapy in IIH management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network, analysing data through November 2024. Through propensity score matching, we compared 193 tirzepatide-exposed IIH patients with 193 controls receiving standard care. Primary outcomes included papilledema severity, visual function, headache frequency, and treatment resistance, monitored at multiple follow-up timepoints.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our analysis revealed significant improvements across all measured outcomes in the tirzepatide group. At 24 months, we observed a 68% reduction in papilledema risk (RR 0.320, 95% CI 0.189–0.542, <i>p</i> &lt; 0.001), a 73.9% reduction in visual disturbance and blindness risk (RR 0.261, 95% CI 0.143–0.477, <i>p</i> &lt; 0.001), and a 19.7% reduction in headache risk (RR 0.803, 95% CI 0.668–0.966, <i>p</i> = 0.019). The tirzepatide group demonstrated significant body-mass index reductions, reaching −1.147 kg/m² (95% CI [−1.415, −0.879], <i>p</i> &lt; 0.001) at 24 months compared to controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our results demonstrate that tirzepatide, when used as an adjunctive therapy, provides significant therapeutic benefits in IIH management, particularly in improving papilledema and visual outcomes. Our findings suggest that dual GIP/GLP-1 receptor activation may offer advantages over traditional single-receptor therapies, potentially through enhanced metabolic regulation and direct effects on ICP dynamics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Alzheimer's-Related Mortality Among Type 2 Diabetes Patients in the United States: 1999–2019","authors":"Saad Ahmed Waqas,&nbsp;Dua Ali,&nbsp;Taimor Mohammed Khan,&nbsp;Shaheer Qureshi,&nbsp;Hibah Siddiqui,&nbsp;Maryam Sajid,&nbsp;Zahra Imran,&nbsp;Hussain Salim,&nbsp;Muhammad Umer Sohail,&nbsp;Raheel Ahmed,&nbsp;Shayan Marsia","doi":"10.1002/edm2.70032","DOIUrl":"https://doi.org/10.1002/edm2.70032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Recent research has shown that type 2 diabetes mellitus (T2DM) has increased the burden of Alzheimer's disease (AD) in the US aging population. However, trends in mortality from this comorbidity among adults aged ≥ 65 years have not been investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study examined trends and disparities in AD-related mortality among older US adults with T2DM from 1999 to 2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from the CDC WONDER database were analysed to assess AD-related mortality in patients with T2DM aged ≥ 65 between 1999 and 2019. Age-adjusted mortality rates (AAMRs) per 100,000 people and annual percent change (APC) were calculated and stratified by year, sex, race/ethnicity, age, urbanisation and geographical region.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 1999 to 2019, there were 71,550 deaths with T2DM and AD among adults aged ≥ 65. AAMRs rose from 4.12 in 1999 to 11.65 in 2019, with the sharpest increase between 2014 and 2017 (APC: 10.81; 95% CI: −3.20 to 13.43). Women had slightly higher AAMRs than men, with rates increasing from 4.71 in 1999 to 11.61 in 2019 for women, and from 4.08 to 11.70 for men. Hispanic individuals saw the highest increase in AAMR (11.15), followed by non-Hispanic Black (9.30) and White populations (7.92). AAMRs were highest in the West (10.91) and the Midwest (9.62), while the Northeast (4.70) had the lowest. Nonmetropolitan areas had consistently higher AAMRs (10.74) than large metropolitan areas (6.68) and small/medium metropolitan areas (9.25). States in the top 90th percentile for T2DM–AD mortality included California, South Dakota and Kentucky, where rates were approximately eight times higher than in states in the lowest 10th percentile.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study reveals a significant rise in T2DM–AD comorbidity-related mortality among older adults, especially among Hispanics, women and rural residents. These findings underscore the need for targeted interventions to reduce the burden in vulnerable populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143111302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between TyG-BMI Index and Hyperuricemia in Adult Women","authors":"Kelibinuer Mutailipu,&nbsp;Junwei Guo,&nbsp;Jiajing Yin,&nbsp;Yue Wang,&nbsp;Liesheng Lu,&nbsp;Xuyang Jia,&nbsp;Jie Zhang,&nbsp;Shen Qu,&nbsp;Haibing Chen,&nbsp;Le Bu","doi":"10.1002/edm2.70028","DOIUrl":"https://doi.org/10.1002/edm2.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>This study aimed to explore the relationship between hyperuricemia (HUA), the triglyceride-glucose index (TyG) and its derivatives in adult women.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional analysis was conducted on 1105 female patients from Shanghai Tenth People's Hospital. Participants were divided into HUA (<i>n</i> = 331) and non-HUA (<i>n</i> = 774) groups. Clinical and laboratory data were collected, and indices such as body mass index (BMI), TyG and TyG-BMI were calculated. Statistical analyses included univariate and multivariate logistic regression and receiver operating characteristic (ROC) curve analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The HUA group showed higher BMI, blood pressure and metabolic parameters. TyG, TyG-BMI and BMI were positively correlated with uric acid levels. ROC analysis revealed that TyG-BMI (AUC = 0.877) had better predictive power for HUA than TyG (AUC = 0.829) or BMI (AUC = 0.867). Multivariate analysis showed TyG-BMI and BMI as independent predictors, with women in the highest quartiles having a 3.111-fold and 2.779-fold higher risk for HUA, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>TyG-BMI is the most effective predictor of HUA in women, surpassing TyG and BMI alone. It offers a practical tool for early identification and intervention in women at risk of HUA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143111303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Serum Free Fatty Acids in Endothelium-Dependent Microvascular Function","authors":"Alexander E. Sullivan,&nbsp;Meaghan C. S. Courvan,&nbsp;Aaron W. Aday,&nbsp;David H. Wasserman,&nbsp;Kevin D. Niswender,&nbsp;Emily M. Shardelow,&nbsp;Emily K. Wells,&nbsp;Quinn S. Wells,&nbsp;Matthew S. Freiberg,&nbsp;Joshua A. Beckman","doi":"10.1002/edm2.70031","DOIUrl":"10.1002/edm2.70031","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Elevated serum free fatty acid (FFA) concentration is associated with insulin resistance and is a hallmark of metabolic syndrome. A pathological feature of insulin resistance is impaired endothelial function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the effect of FFA reduction with either acipimox, a nicotinic acid derivative that impairs lipolysis, or salsalate, a salicylate that reduces basal and inflammation-induced lipolysis, on insulin-mediated endothelium-dependent vasodilation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a post hoc, combined analysis of two randomised, double-blind, placebo-controlled crossover trials. Sixteen subjects were recruited (6 with metabolic syndrome and 10 controls) and randomised to acipimox 250 mg orally every 6 h for 7 days or placebo. Nineteen subjects were recruited (13 with metabolic syndrome and 6 controls) and randomised to receive salsalate 4.5 g/day for 4 weeks or placebo. The primary outcome was the association between FFA concentration and insulin-mediated vasodilation, measured by venous-occlusion strain-gauge plethysmography at baseline and following FFA modulation with the study drugs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At baseline, FFA concentration (<i>R</i> = −0.35, <i>p</i> = 0.043) and insulin sensitivity (HOMA-IR: <i>R</i> = −0.42, <i>p</i> = 0.016, Adipo-IR: <i>R</i> = −0.39, <i>p</i> = 0.025) predicted insulin-mediated vasodilation. FFA levels were significantly reduced after drug pretreatment (0.604 vs. 0.491 mmol/L, <i>p</i> = 0.036) while insulin levels, insulin sensitivity and inflammatory markers were unchanged. Despite a reduction in circulating FFA with drug therapy, neither insulin-stimulated vasodilation nor insulin sensitivity improved.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Short-term reduction of FFA concentration does not improve insulin-stimulated vasodilation in patients with metabolic syndrome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT00759291 and NCT00760019 (formerly NCT00762827)</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143071194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Albumin-To-Creatinine Ratio With Diabetic Retinopathy Among US Adults (NHANES 2009–2016)","authors":"Han Dai,&nbsp;Ling Liu,&nbsp;Weiwei Xu","doi":"10.1002/edm2.70029","DOIUrl":"10.1002/edm2.70029","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study investigates the relationship between the albumin-to-creatinine ratio and diabetic retinopathy (DR) in US adults using NHANES data from 2009 to 2016. This study assesses the predictive efficacy of the urinary serum albumin-to-creatinine ratio (UACR/SACR Ratio) against traditional biomarkers such as the serum albumin-to-creatinine ratio (SACR) and urinary albumin-to-creatinine ratio (UACR) for evaluating DR risk. Additionally, the study explores the potential of these biomarkers, both individually and in combination with HbA1c, for early detection and risk stratification of DR.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This cross-sectional study analysed data from 2594 diabetic adults in the National Health and Nutrition Examination Survey (NHANES 2009–2016). Multivariate logistic regression models, adjusted for demographic (sex, age, race and education) and clinical factors (WBC, PLT, RDW, HbA1c, HBP and CHD), examined the associations between biomarkers and DR. Biomarkers were analysed both continuously and in quartiles to assess dose–response relationships. Receiver operating characteristic (ROC) curve analysis evaluated the predictive accuracy of individual biomarkers and combined models.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Elevated SACR levels were inversely related to DR risk, while UACR showed a positive correlation. The UACR/SACR ratio demonstrated superior predictive capability for DR compared to SACR and UACR alone. The most accurate predictive model combined SACR, UACR, UACR/SACR ratio and HbA1c (AUC = 0.614), highlighting DR development complexity. Subgroup analyses revealed stronger associations in participants aged &lt; 60 years and those with hypertension (both &lt;i&gt;p&lt;/i&gt; &lt; 0.05), with more pronounced effects observed in males and Mexican Americans, while lifestyle factors showed no significant modifying effect.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The UACR/SACR Ratio emerged as a potentially superior DR predictor, particularly in younger patients and those with hypertension, suggesting its utility in enhancing early detection and risk stratification. Comprehensive evaluation of renal function and glycaemic control biomarkers, considering age- and comorbidity-specific patterns, could improve DR risk prediction and management. Future longitudinal studies should validate these findings, particularly in identified high-risk subgroups, and investigate underlying mechanisms, potentially advancing personalised DR prediction and management strategies.&lt;/p&gt;\u0000 ","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Predictive Role of 11-Oxyandrogens in Diagnosing Polycystic Ovary Syndrome","authors":"Armaiti Parvez Mody,&nbsp;Maya Beth Lodish,&nbsp;Richard Joseph Auchus,&nbsp;Adina F. Turcu,&nbsp;Fei Jiang,&nbsp;Heather Gibson Huddleston","doi":"10.1002/edm2.70022","DOIUrl":"10.1002/edm2.70022","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Context&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Hyperandrogenism is a hallmark of polycystic ovary syndrome (PCOS), yet the androgen(s) responsible remain ambiguous. Recent studies have suggested that 11-oxygenated C&lt;sub&gt;19&lt;/sub&gt; steroids (11-oxyandrogens), specifically 11-ketotestosterone, may be a good marker for hyperandrogenism in PCOS.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To investigate the utility of 11-oxyandrogens to differentiate women with and without PCOS relative to classical androgens.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Case–control study performed at a PCOS clinic and research center in an academic setting.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Patients&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;114 women with PCOS and 78 healthy controls.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Interventions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Using the PCOS Tissue Bank, serum samples and data from 114 women registered from 2013 to 2017 between the ages of 18–40 years, were obtained and classified using Rotterdam PCOS criteria. Data were compared to 78 healthy women of similar age, with serum samples obtained between 2017 and 2020. 11-oxyandrogens and sex steroids were measured using mass spectrometry, and their associations to Rotterdam PCOS, age, and BMI were assessed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;11-oxyandrogens and sex steroids.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Total testosterone, androstenedione, and four 11-oxyandrogens were significantly elevated in women with PCOS compared to age matched controls, controlling for age and BMI (&lt;i&gt;p&lt;/i&gt; &lt; 0.01 for all). When considered together, the four 11-oxyandrogens were more predictive of PCOS compared to testosterone and androstenedione. When all androgens were considered individually, 11-ketoandrostenedione was the most predictive of PCOS. Of the six androgens studied, 11-ketotestosterone was the only androgen that demonstrated a weak association with hirsutism score (&lt;i&gt;r&lt;/i&gt; = 0.17; &lt;i&gt;p&lt;/i&gt; = 0.07) within the PCOS group.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;11-oxyandrogens were statistically higher in women with PCOS and may serve as better predictors of PCOS than testosterone and androstenedione.&lt;/p&gt;\u0000 ","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions for Type 2 Diabetes Prevention and Management Among Indigenous Children and Youth: A Systematic Review","authors":"Edmund Wedam Kanmiki,&nbsp;Yaqoot Fatima,&nbsp;Thuy Linh Duong,&nbsp;Roslyn Von Senden,&nbsp;Tolassa W. Ushula,&nbsp;Abdullah A. Mamun","doi":"10.1002/edm2.70026","DOIUrl":"10.1002/edm2.70026","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Indigenous populations experience a disproportionately higher burden of early onset of type 2 diabetes mellitus (T2DM). To contribute towards addressing this health disparity, evidence-based culturally appropriate interventions are urgently needed. This systematic review examines interventions designed to improve the prevention and management of T2DM among Indigenous children and youth.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive search of five electronic databases was carried out in February 2023 to identify relevant studies published in English. We included studies of all designs involving Indigenous children and youth under 25 years of age. An adapted version of the National Institute of Health (NIH) quality assessment tool for pre-post intervention studies was used for quality assessment. Due to the heterogeneity of methods used by reviewed publications, the convergent integrated approach developed by Joanna Briggs Institute (JBI) for mixed-method systematic reviews was employed in the analysis. Prospero registration ID: CRD42023423671.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The search identified 1127 publications, and 25 studies with a total of 4594 participants from four countries were eligible after screening. Notably, most (80%) originated from North America. Most interventions involved &lt; 100 participants and lasted 6 months or less (58%). While knowledge and behaviours improved for most interventions, longer and culturally responsive interventions, often combining both community and school-based elements, demonstrated a greater effect on key anthropometrics and biomarkers associated with the risk of T2DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This review highlights the urgent need for more research to address T2DM among Indigenous youth. Future research should prioritise culturally appropriate, long-term interventions that engage communities and empower Indigenous youth to make healthy choices.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}